Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420–9.

Article  PubMed  Google Scholar 

Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22(Suppl):1.

Google Scholar 

Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158–65.

Article  PubMed  Google Scholar 

Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–62.

Article  CAS  Google Scholar 

Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135:2899–910.

Article  PubMed  Google Scholar 

Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53.

Article  CAS  PubMed  Google Scholar 

Song Z, Zhou L, Xue Y, et al. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25: e12762.

Article  CAS  PubMed  Google Scholar 

Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:1815–22.

Article  CAS  PubMed  Google Scholar 

Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160:1831–41.

Article  PubMed  Google Scholar 

Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 2017;23:2854–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25: e12692.

Article  CAS  PubMed  Google Scholar 

Han YY, Fang D, Guan JL, et al. Research and progress of amoxicillin and proton pump inhibitor dual therapy for Helicobacter pylori infection. Chin J Dig. 2022;42:137–40.

Google Scholar 

Labenz J, Gyenes E, Rühl GH, et al. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993;88:491–5.

CAS  PubMed  Google Scholar 

Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol. 2015;6: e94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyu QJ, Pu QH, Zhong XF, et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019;2019:9781212.

Article  PubMed  PubMed Central  Google Scholar 

Hou X, Meng F, Wang J, et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. J Gastroenterol Hepatol. 2022;37:1275–83.

Article  CAS  PubMed  Google Scholar 

Ouyang Y, Wang M, Xu YL, et al. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:1666–72.

Article  CAS  PubMed  Google Scholar 

Kuo CH, Lu CY, Shih HY, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20:16029–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan JL, Hu YL, An P, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial. Pharmacotherapy. 2022;42:224–32.

Article  CAS  PubMed  Google Scholar 

Han YY, Long H, Lin Y, et al. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: a large-scale prospective, multicenter, open-label, randomized controlled study. Helicobacter. 2022;27: e12922.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14:1259–66.

Article  CAS  PubMed  Google Scholar 

Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44:458–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao W, Ye H, Deng X, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: a retrospective, real-life study. Helicobacter. 2020;25: e12717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shao QQ, Yu XC, Yu M, et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: a single-center, prospective, open-label, randomized-controlled trial. Helicobacter. 2022;27: e12876.

Article  CAS  PubMed  Google Scholar 

Federico A, Gravina AG, Miranda A, et al. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol. 2014;20:665–72.

Article  PubMed  PubMed Central  Google Scholar 

Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised edition. Helicobacter. 2019;24:e12597.

Article  PubMed  Google Scholar 

Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093–112.

Article  PubMed  Google Scholar 

Gotoda T, Kusano C, Suzuki S, et al. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J Gastroenterol. 2020;55:969–76.

Article  CAS  PubMed  Google Scholar 

Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019–26.

Article  CAS  PubMed  Google Scholar 

Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39:465–80.

Article  PubMed  Google Scholar 

Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020;101:743–51.

Article  CAS  PubMed  Google Scholar 

Sue S, Kondo M, Sato T, et al. Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: a single-arm, interventional study. JGH Open. 2022;7:55–60.

Article  PubMed  PubMed Central  Google Scholar 

Horii T, Suzuki S, Takano C, et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021;36:3314–21.

Article  CAS  PubMed  Google Scholar 

Hu Y, Xu X, Ouyang YB, et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: a prospective, randomized clinical pilot study. Helicobacter. 2022;27: e12896.

Article  CAS  PubMed  Google Scholar 

Hu Y, Xu X, Liu XS, et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2023;13:1049908.

Article  PubMed  PubMed Central  Google Scholar 

Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118:627–34.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Zhu YJ, Zhao Z, et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol. 2020;32:563–8.

Article  CAS  PubMed  Google Scholar 

Zou PY, Hu J, Zhao JT, et al. 10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: a propensity score matching analysis. Helicobacter. 2021;26: e12833.